Nicox Provides Full Year 2025 Financial Results and Corporate Update

About this update from Nicox Sa

[{"type":"image","alt":"NICOX SA","displaySize":"","headline":null,"caption":"NICOX SA","className":"","disableSlideshowImg":false,"size":{"original":{"width":290,"height":177,"url":"https://media.zenfs.com/en/globenewswire.com/e5c6c949c0184e4a40b35f1bde81d2f8"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/hupAKiVg0xhl4ojs_SOLZw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTI1Ng--/https://media.zenfs.com/en/globenewswire.com/e5c6c949c0184e4a40b35f1bde81d2f8","width":290,"height":177}},"lazy":false},{"type":"table","headerItems":[],"items":[{"val":[{"style":"width:633.14px;border-bottom:solid black 1pt;vertical-align:top;","val":[{"type":"text","content":"Press Release ","length":13,"tagName":"p","attribs":{}}]}]},{"val":[{"style":"width:633.14px;border-top:solid black 1pt;border-bottom:solid black 1pt;text-align:justify;vertical-align:middle;vertical-align:top;","val":[{"type":"text","content":"Nicox Provides Full Year 2025 Financial Results and Corporate Update","length":68,"tagName":"p","attribs":{}}]}]},{"val":[{"style":"width:633.14px;vertical-align:top;","val":[{"type":"text","content":"","length":0,"tagName":"p","attribs":{}},{"type":"list","items":[{"val":[{"type":"text","content":"Revenue of €16.8 million (€7.9 million in 2024) ","length":47,"tagName":"p"}]},{"val":[{"type":"text","content":"Net loss significantly reduced to €2.4 million (€22.4 million in 2024)","length":70,"tagName":"p"}]},{"val":[{"type":"text","content":"NCX 470 U.S. New Drug Application (NDA) submission on track for summer 2026, with associated milestone payment","length":110,"tagName":"p"}]},{"val":[{"type":"text","content":"Regulatory milestones anticipated to extend cash runway beyond 2027 ","length":67,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":294,"olType":false},{"type":"text","content":"April 30, 2026 – release at 7:30 am CET Sophia Antipolis, FranceNicox SA (Euronext Growth Paris: FR0013018124, ALCOX), an international ophthalmology company, today announced its financial results for the full year of 2025, as approved by the Board of Directors on 29 April 2026, and provided an update on key future milestones. “2025 marked a pivotal turning point for Nicox,” said Gavin Spencer, Chief Executive Officer of Nicox. “We have significantly strengthened our financial position, reduced our net loss and eliminated secured debt, removing a number of long-term oblig...

More updates from Nicox Sa